Longeveron (LGVN) Liabilities and Shareholders Equity (2021 - 2026)

Longeveron's (LGVN) quarterly Liabilities and Shareholders Equity came in at $21.2 million in Q1 2026, up 1.74% year-on-year from $20.8 million in Q1 2025, and up 106.7% quarter-over-quarter from $10.3 million in Q4 2025.

Longeveron (LGVN) Liabilities and Shareholders Equity (2021 - 2026) Analysis & Trends

Longeveron's Liabilities and Shareholders Equity history runs 6 years deep, the most recent figure standing at $21.2 million for Q1 2026.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 1.74% year-over-year to $21.2 million in Q1 2026; TTM through Mar 2026 was $63.8 million, a 33.36% decrease from a year earlier, with the FY2025 full-year figure at $10.3 million, down 59.85% from the prior year.
  • Liabilities and Shareholders Equity improved to $21.2 million in Q1 2026 per LGVN's latest filing, from $10.3 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $29.9 million in Q3 2024 and bottomed at $9.7 million in Q1 2024.
  • The 5-year median for Liabilities and Shareholders Equity is $18.2 million (2023), against an average of $18.5 million.
  • Across the five-year window, Liabilities and Shareholders Equity surged 157.28% in 2024 and sank 59.85% in 2025, its largest moves.
  • Year by year, Liabilities and Shareholders Equity stood at $27.4 million in 2022, then sank by 55.94% to $12.1 million in 2023, then soared by 111.61% to $25.6 million in 2024, then sank by 59.85% to $10.3 million in 2025, then jumped by 106.7% to $21.2 million in 2026.
  • Per Business Quant, the three latest LGVN Liabilities and Shareholders Equity figures stand at $21.2 million (Q1 2026), $10.3 million (Q4 2025), and $15.6 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 311.58 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 78.88 Mn
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 8.55 Bn
4 NuCana 279.75 Bn 279.75 Bn - 39.68 Mn
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 26.48 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 40.87 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - 811.27 Mn
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 10.03 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn - 2.25 Bn
10 Longeveron 3.97 Mn -11.79 Mn 264,000.00 21.21 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 21.21 Mn
Dec 31, 2025 10.26 Mn
Sep 30, 2025 15.56 Mn
Jun 30, 2025 16.75 Mn
Mar 31, 2025 20.85 Mn
Dec 31, 2024 25.56 Mn
Sep 30, 2024 29.91 Mn
Jun 30, 2024 19.39 Mn
Mar 31, 2024 9.70 Mn
Dec 31, 2023 12.08 Mn
Sep 30, 2023 11.63 Mn
Jun 30, 2023 17.09 Mn
Mar 31, 2023 21.81 Mn
Dec 31, 2022 27.41 Mn
Dec 31, 2021 42.77 Mn